304 related articles for article (PubMed ID: 24700690)
21. Inherited craniofacial fibrous dysplasia.
Pierce AM; Wilson DF; Goss AN
Oral Surg Oral Med Oral Pathol; 1985 Oct; 60(4):403-9. PubMed ID: 3864099
[TBL] [Abstract][Full Text] [Related]
22. Familial craniofacial fibrous dysplasia: absence of linkage to GNAS1 and the gene for cherubism.
Mangion J; Edkins S; Goss AN; Stratton MR; Flanagan AM
J Med Genet; 2000 Nov; 37(11):E37. PubMed ID: 11073546
[No Abstract] [Full Text] [Related]
23. Development and Validation of a Simple Diagnostic Method to Detect Gain and Loss of Function Defects in Fibroblast Growth Factor-23.
Ramadan AR; Shawar SM; Alghamdi MA
Horm Res Paediatr; 2016; 86(1):45-52. PubMed ID: 27355663
[TBL] [Abstract][Full Text] [Related]
24. Novel genetic mutation associated with hyperphosphatemic familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome treated with denosumab: a case report.
Fabbriciani G; Colombini A; Messina C; Adami G
Reumatismo; 2024 Jun; 76(2):. PubMed ID: 38916164
[TBL] [Abstract][Full Text] [Related]
25. Mineralization defects in cementum and craniofacial bone from loss of bone sialoprotein.
Foster BL; Ao M; Willoughby C; Soenjaya Y; Holm E; Lukashova L; Tran AB; Wimer HF; Zerfas PM; Nociti FH; Kantovitz KR; Quan BD; Sone ED; Goldberg HA; Somerman MJ
Bone; 2015 Sep; 78():150-64. PubMed ID: 25963390
[TBL] [Abstract][Full Text] [Related]
26. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations.
Ichikawa S; Baujat G; Seyahi A; Garoufali AG; Imel EA; Padgett LR; Austin AM; Sorenson AH; Pejin Z; Topouchian V; Quartier P; Cormier-Daire V; Dechaux M; Malandrinou FCh; Singhellakis PN; Le Merrer M; Econs MJ
Am J Med Genet A; 2010 Apr; 152A(4):896-903. PubMed ID: 20358599
[TBL] [Abstract][Full Text] [Related]
27. Hyperphosphatemic familial tumoral calcinosis in a dancer.
Li WX; Stanek J
PM R; 2023 May; 15(5):685-687. PubMed ID: 35445589
[No Abstract] [Full Text] [Related]
28. FGF23-S129F mutant bypasses ER/Golgi to the circulation of hyperphosphatemic familial tumoral calcinosis patients.
Shawar SM; Ramadan AR; Ali BR; Alghamdi MA; John A; Hudaib FM
Bone; 2016 Dec; 93():187-195. PubMed ID: 26620085
[TBL] [Abstract][Full Text] [Related]
29. Massive osteolysis (Gorham-Stout syndrome) in the maxillofacial region: an unusual manifestation.
Klein M; Metelmann HR; Gross U
Int J Oral Maxillofac Surg; 1996 Oct; 25(5):376-8. PubMed ID: 8961021
[TBL] [Abstract][Full Text] [Related]
30. [Genetic basis for skeletal disease. Dental management of patients with bone diseases].
Shintani S; Ooshima T
Clin Calcium; 2010 Aug; 20(8):1259-65. PubMed ID: 20675938
[TBL] [Abstract][Full Text] [Related]
31. Hyperphosphatemic tumoral calcinosis caused by FGF23 compound heterozygous mutations: what are the therapeutic options for a better control of phosphatemia?
Claramunt-Taberner D; Bertholet-Thomas A; Carlier MC; Dijoud F; Chotel F; Silve C; Bacchetta J
Pediatr Nephrol; 2018 Jul; 33(7):1263-1267. PubMed ID: 29594503
[TBL] [Abstract][Full Text] [Related]
32. Dialysis as a Treatment Option for a Patient With Normal Kidney Function and Familial Tumoral Calcinosis Due to a Compound Heterozygous FGF23 Mutation.
Goldenstein PT; Neves PD; Balbo BE; Elias RM; Pereira AC; Onuchic LF; Jüppner H; Jorgetti V; Abensur H; Moysés RM
Am J Kidney Dis; 2018 Sep; 72(3):457-461. PubMed ID: 29548779
[TBL] [Abstract][Full Text] [Related]
33. Gorham-Stout syndrome of the facial bones: a review of pathogenesis and treatment modalities and report of a case with a rare cutaneous manifestations.
Al-Jamali J; Glaum R; Kassem A; Voss PJ; Schmelzeisen R; Schön R
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Dec; 114(6):e23-9. PubMed ID: 23159123
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and management of pediatric metabolic bone diseases associated with skeletal fragility.
Charoenngam N; Cevik MB; Holick MF
Curr Opin Pediatr; 2020 Aug; 32(4):560-573. PubMed ID: 32692054
[TBL] [Abstract][Full Text] [Related]
35. A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.
Dumitrescu CE; Kelly MH; Khosravi A; Hart TC; Brahim J; White KE; Farrow EG; Nathan MH; Murphey MD; Collins MT
Osteoporos Int; 2009 Jul; 20(7):1273-8. PubMed ID: 18982401
[TBL] [Abstract][Full Text] [Related]
36. [Familial expansive osteolysis otological and dental manifestations of genetic origin].
Font N
Ann Otolaryngol Chir Cervicofac; 2004 Dec; 121(6):360-72. PubMed ID: 15711475
[TBL] [Abstract][Full Text] [Related]
37. Biological stenciling of mineralization in the skeleton: Local enzymatic removal of inhibitors in the extracellular matrix.
Reznikov N; Hoac B; Buss DJ; Addison WN; Barros NMT; McKee MD
Bone; 2020 Sep; 138():115447. PubMed ID: 32454257
[TBL] [Abstract][Full Text] [Related]
38. Human Preosteoblastic Cell Culture from a Patient with Severe Tumoral Calcinosis-Hyperphosphatemia Due to a New GALNT3 Gene Mutation: Study of In Vitro Mineralization.
Masi L; Beltrami G; Ottanelli S; Franceschelli F; Gozzini A; Zonefrati R; Galli G; Ciuffi S; Mavilia C; Giusti F; Marcucci G; Cioppi F; Colli E; Fossi C; Franchi A; Casentini C; Capanna R; Brandi ML
Calcif Tissue Int; 2015 May; 96(5):438-52. PubMed ID: 25899975
[TBL] [Abstract][Full Text] [Related]
39. Genetic modes of transmission in metabolic bone disease.
Jackson CE; Mock LF
Clin Orthop Relat Res; 1970; 68():238-50. PubMed ID: 4313225
[No Abstract] [Full Text] [Related]
40. [Fibroblast growth factor 23--a phosphate regulating hormone].
Beck-Nielsen SS; Pedersen SM; Kassem M; Rasmussen LM
Ugeskr Laeger; 2010 May; 172(20):1521-7. PubMed ID: 20483099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
